Bluebird bio Inc logo

BLUE

Bluebird bio Inc

$5.91

Earnings Summary

Revenue
$1.95Mn
Net Profits
$-122.15Mn
Net Profit Margins
-6280.31%

Highlights

Revenue:

Bluebird bio Inc’s revenue fell -84.8% since last year same period to $1.95Mn in the Q1 2022. On a quarterly growth basis, Bluebird bio Inc has generated 104.95% jump in its revenue since last 3-months.

Net Profits:

Bluebird bio Inc’s net profit jumped 40.65% since last year same period to $-122.15Mn in the Q1 2022. On a quarterly growth basis, Bluebird bio Inc has generated 21.22% jump in its net profits since last 3-months.

Net Profit Margins:

Bluebird bio Inc’s net profit margin fell -290.41% since last year same period to -6280.31% in the Q1 2022. On a quarterly growth basis, Bluebird bio Inc has generated -1691.06% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Bluebird bio Inc post its latest quarter earnings

EPS Estimate Current Quarter
-1.24
EPS Estimate Current Year
-1.24

Highlights

EPS Estimate Current Quarter:

Bluebird bio Inc’s earning per share (EPS) estimates for the current quarter stand at -1.24 - a 10.79% jump from last quarter’s estimates.

EPS Estimate Current Year:

Bluebird bio Inc’s earning per share (EPS) estimates for the current year stand at -1.24.

Key Ratios

Key ratios of the Bluebird bio Inc post its Q2 2022 earnings

Return on Assets (ROA)
-0.3
Return on Equity (ROE)
-0.87
Dividend Per Share (DPS)
0

Highlights

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Bluebird bio Inc’s return on assets (ROA) stands at -0.3.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Bluebird bio Inc’s return on equity (ROE) stands at -0.87.

Dividend Per Share (DPS):

Bluebird bio Inc declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-09
-1.39
-1.66
-19.42%

Company Information

bluebird bio is pioneering gene therapy with purpose. From its Cambridge, Mass., headquarters, they're developing gene and cell therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond their labs, the company is working to positively disrupt the healthcare system to create access, transparency and education so that gene therapy can become available to all those who can benefit.

Organisation
Bluebird bio Inc
Employees
1.21K
Industry
Health Technology